Vicapsys Life Sciences, Inc. (VICP)
OTCMKTS: VICP · Delayed Price · USD
2.720
0.00 (0.00%)
Jun 21, 2024, 9:50 AM EDT - Market closed
Company Description
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product.
The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field.
It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers.
The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017.
Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.
Vicapsys Life Sciences, Inc.
| Country | GA |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Federico Pier |
Contact Details
Address: 1735 Buford Highway, Ste. 215-113 Cumming, Georgia 30041 United States | |
| Phone | 470-514-4013 |
| Website | vicapsys.com |
Stock Details
| Ticker Symbol | VICP |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001468639 |
| CUSIP Number | 92560A106 |
| ISIN Number | US92560A1060 |
| Employer ID | 62-1153426 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Federico Pier | Chief Executive Officer, Executive Chairman and Interim President |
| Jeffery Wright CPA, CPA | Chief Financial Officer |
| Dr. Mark C. Poznansky M.D., Ph.D. | Chief Scientist Advisor and Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 27, 2023 | 8-K | Current Report |
| Nov 14, 2023 | 10-Q | Quarterly Report |
| Aug 14, 2023 | 10-Q | Quarterly Report |
| Aug 9, 2023 | DEF 14C | Filing |
| Jul 28, 2023 | PRE 14C | Filing |
| Jul 13, 2023 | D | Notice of Exempt Offering of Securities |
| Jun 30, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 30, 2023 | 8-K | Current Report |
| Jun 2, 2023 | 8-K | Current Report |
| May 18, 2023 | 8-K/A | [Amend] Current report |